Mineralys Therapeutics CMO Rodman Executes Pre-Arranged Share Sales Under Rule 10b5-1 Plan
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Chief Medical Officer Rodman David Malcom executed two separate sales of company common stock totaling $556,671 on July 13 and July 15, 2026. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on October 6, 2025. Concurrently with the initial sale on July 13, Mr. Malc…